AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27959713
Drug: Very-low-dose rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months
Trial: 27959713
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with a dose-adjusted vitamin K antagonist plus DAPT for 1, 6, or 12 months
Trial: 20600481
Drug: Intradermal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal delivery using BD microneedle technology at 1/4 the IM antigen dose
Trial: 8443746
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy after liver metastasis resection
Trial: 19884008
Drug: Metronomic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronomic administration of pegylated liposomal-doxorubicin (PLD) at a dosage of 20mg/m² i.v. every two weeks
Trial: 19082804
Drug: Cobamamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobamamide (2 tablets) orally and Psoralea tincture externally thrice a day for 3 months (Control group)
Trial: 19082804
Drug: Zengse Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zengse Pill (ZSP)
Trial: 14514497
Drug: Antidepressants (nortriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (nortriptyline or fluoxetine)
Trial: 10772083
Drug: 3-drug arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-drug arm (rifabutin 600 mg daily, ethambutol 15 mg/kg daily, clarithromycin 1000 mg twice daily)
Trial: 10772083
Drug: 4-drug arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-drug arm (rifampin 600 mg, ethambutol 15 mg/kg daily, clofazimine 100 mg daily, ciprofloxacin 750 mg twice daily)
Trial: 25415292
Drug: 3-drug arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-drug arm
Trial: 22727709
Drug: Duloxetine (60-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60-120 mg/d)
Trial: 20465434
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil enriched with n-3 PUFA (6.5 ml daily for 12 months)
Trial: 17650833
Drug: Ciclesonide, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide, 200 microg once daily
Trial: 12140346
Drug: Monthly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly telephone monitoring of psychological distress and home nursing visits
Trial: 7755223
Drug: Recombinant glycoprotein
RxNorm normalized name: Recombinant glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant glycoprotein vaccine (gD2 and gB2 with MF59 adjuvant) administered intramuscularly at 0, 1, and 6 months
Trial: 25175495
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg THC + 0 mg MPH
Trial: 25175495
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg THC + 40 mg MPH
Trial: 20973909
Drug: Operative time,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative time, estimated blood loss (EBL), postoperative stay, analgesics use, changes in creatinine and haemoglobin levels, postoperative SF-36 scores
Trial: 19884550
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (10,000 U SC three times weekly if baseline Hb < 12.5 g/dL; 4,000 U SC three times weekly if baseline Hb >= 12.5 g/dL)
Trial: 17132120
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (six sessions)
Trial: 16329348
Drug: Fexofenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine (120 mg/d for 10 days)
Trial: 16329348
Drug: Fluticasone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (200 mcg/d for 10 days)
Trial: 11504959
Drug: IDV +
RxNorm normalized name: Indinavir
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IDV + ddI + d4T + hydroxyurea (HU) (600 mg twice daily)
Trial: 20096432
Drug: Ghrelin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (3 microg/kg) administered intravenously twice daily for 10 days
Trial: 10671656
Drug: Adjuvant radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiation therapy
Trial: 7601014
Drug: Spirapril ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril ≥ 6 mg once daily
Trial: 7601014
Drug: Spirapril (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril (monotherapy or in combination with hydrochlorothiazide)
Trial: 28407247
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (NHT) for RS < 11
Trial: 28407247
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (NHT) for RS 11-25
Trial: 28407247
Drug: Chemotherapy (NCT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (NCT) for RS 11-25
Trial: 28407247
Drug: Chemotherapy (NCT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (NCT) for RS > 25
Trial: 11426667
Drug: Intravenous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered twice weekly (group 2)
Trial: 11426667
Drug: Intravenous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered thrice weekly (group 3)
Trial: 11426667
Drug: Intravenous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered once weekly (group 1)
Trial: 3081599
Drug: Cromolyn (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn (20 mg)
Trial: 2879970
Drug: Chlorproguanil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorproguanil 20 mg weekly
Trial: 26688437
Drug: Structural group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structural group therapy
Trial: 23457678
Drug: Inhaled menthol
RxNorm normalized name: menthol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled menthol
Trial: 11587994
Drug: Sham inhalation
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham inhalation
Trial: 9031393
Drug: Quinine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 600 mg tid for 5 days + Tetracycline 250 mg qid for 7 days (Q5T7; group A)
Trial: 9031393
Drug: Quinine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 600 mg tid for 7 days + Tetracycline 250 mg qid for 7 days (Q7T7; group B)
Trial: 1688971
Drug: Intravenous dibutyryl
RxNorm normalized name: Dibutyl Phthalate
DrugBank: Dibutylphthalate (DB13716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dibutyryl cyclic AMP (DBcyclicAMP)
Trial: 11426360
Drug: Intravenous dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dobutamine
Trial: 28722627
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) alone without additional screening by CHWs.
Trial: 12605289
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg daily for 6 days)
Trial: 12605289
Drug: Reboxetine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (8 mg daily for 6 days)
Trial: 2757957
Drug: Topical psoralen
RxNorm normalized name: Psoralen
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical psoralen photochemotherapy (topical PUVA)
Trial: 619946
Drug: Suxamethonium (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium (0.08 mg/kg)
Trial: 619946
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (before drug administration)
Trial: 30509312
Drug: Atezolizumab (anti-PD-L1)
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab (anti-PD-L1) plus chemotherapy
Trial: 25899314
Drug: Diclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (100 mg preoperative dose)
Trial: 23878845
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine solution (Concepsis, Ultradent) applied on the etched dentin for 60 seconds
Trial: 12892690
Drug: Large pad
RxNorm normalized name: ISOPROPYL ALCOHOL 0.7 mL in 1 mL TOPICAL CLOTH [Alcohol Prep Pad Large Pad]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large pad loss (42 g)
Trial: 12892690
Drug: Small pad
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small pad loss (7 g)
Trial: 10481920
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg Kwai garlic
Trial: 10252496
Drug: Linear self-instructional
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linear self-instructional program on the nature and treatment of IHD
Trial: 27696703
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (could include ambulatory physical therapy)
Trial: 19551762
Drug: Topiramate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (300 mg/day) and Aripiprazole (30 mg/day)
Trial: 17580388
Drug: Steroids according
RxNorm normalized name: clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroids according to ISKDC regimen
Trial: 10677093
Drug: Beta carotene,
RxNorm normalized name: Beta Carotene, 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta carotene, 50 mg, on alternate days
Trial: 2184694
Drug: nalbuphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 0.1 mg/kg
Trial: 8442961
Drug: droperidol 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 0.025 mg/kg
Trial: 3715980
Drug: Isoniazid daily
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid daily at 20 mg/kg
Trial: 3715980
Drug: Isoniazid daily
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid daily at 12 mg/kg
Trial: 3715980
Drug: Rifampicin administered
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin administered twice a week
Trial: 3715980
Drug: All regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All regimens (including steroids)
Trial: 30064406
Drug: Single-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent chemotherapy combined with bevacizumab
Trial: 23285702
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cefuroxime axetil film-coated tablets (test product)
Trial: 20630128
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum alkaline phosphatase (>= 97 IU/l)
Trial: 20630128
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum alkaline phosphatase (< 97 IU/l)
Trial: 10465076
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (5000 IU retinyl palmitate and 30 mg beta-carotene during the third trimester, 200000 IU retinyl palmitate at delivery)
Trial: 2653391
Drug: Flosequinan 100
RxNorm normalized name: flosequinan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosequinan 100 mg daily
Trial: 9579492
Drug: Meperidine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (target plasma concentration of 1.2 microg/ml)
Trial: 9579492
Drug: Alfentanil (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (target plasma concentration of 0.2 microg/ml)
Trial: 7659765
Drug: Active TRP
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TRP depletion followed by intranasal cocaine
Trial: 7659765
Drug: Sham depletion
RxNorm normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham depletion followed by intranasal cocaine
Trial: 6251114
Drug: FK 33824
RxNorm normalized name: FK-960
DrugBank: FK-960 (DB06465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK 33824 (0.5 mg i.m.)
Trial: 23373103
Drug: Intravenous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous furosemide at a dose equivalent to the daily oral dose
Trial: 9706945
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine system (TD-NICO) 21 mg/d for at least 10 h before anesthesia
Trial: 9706945
Drug: Abstinent group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinent group (ABST) with placebo transdermal system
Trial: 9706945
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine system (TD-NICO)
Trial: 7621689
Drug: Soft jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft jelly capsules containing nonoxynol
Trial: 19244932
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with glucose polymer (252 g) for 5 days (PL‐GP)
Trial: 19244932
Drug: Creatine (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (21 g) with glucose polymer (252 g) for 5 days (CR‐GP)
Trial: 12466506
Drug: Rate-control therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rate-control therapy
Trial: 12950123
Drug: Oral tegafur-uracil
RxNorm normalized name: tegafur / uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tegafur-uracil plus folinic acid (UFT group)
Trial: 12950123
Drug: Intravenous 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5-fluorouracil plus folinic acid (5-FU group)
Trial: 10904241
Drug: Telmisartan 40-120
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40-120 mg
Trial: 8738587
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (UF heparin)
Trial: 1548522
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (n = 160)
Trial: 25015027
Drug: MPH-LA 60
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPH-LA 60 mg/day
Trial: 25015027
Drug: MPH-LA 80
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPH-LA 80 mg/day
Trial: 23129008
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of 150 × 10^6 BMCs
Trial: 23129008
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of BMCs at day 3
Trial: 23129008
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of BMCs at day 7
Trial: 23129008
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of BMCs
Trial: 15928685
Drug: Fortified pasteurised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified pasteurised milk (200 µg folic acid)
Trial: 12721666
Drug: Celecoxib (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (maximum single dose 200 mg, cumulative daily dose 350 mg)
Trial: 29745006
Drug: 30 min
RxNorm normalized name: Goddess Garden SPF 30 Mineral Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 min of intradialytic exercise (IDEX) in the first hour of treatment
Trial: 29745006
Drug: 30 min
RxNorm normalized name: Goddess Garden SPF 30 Mineral Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 min of intradialytic exercise (IDEX) in the third hour of treatment
Trial: 26892910
Drug: Refusal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refusal of Nicotine Replacement Therapy (NRT)
Trial: 20851230
Drug: 0.02 mg
RxNorm normalized name: escin 0.02 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate (CMA)
Trial: 31605392
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 10 mL
Trial: 7617541
Drug: Multiple-dose terodiline
RxNorm normalized name: terodiline
DrugBank: Terodiline (DB13725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose terodiline (12.5 mg b.i.d. for 14 days)
Trial: 7617541
Drug: Multiple-dose terodiline
RxNorm normalized name: terodiline
DrugBank: Terodiline (DB13725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose terodiline (25 mg b.i.d. for 14 days)
Trial: 7617541
Drug: Overall terodiline
RxNorm normalized name: terodiline
DrugBank: Terodiline (DB13725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall terodiline treatment
Trial: 6327190
Drug: Veralipride 100
RxNorm normalized name: veralipride 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veralipride 100 mg per day for 20 days
Trial: 6327190
Drug: Conjugated oestrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated oestrogens 1.25 mg per day for 20 days
Trial: 28678622
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (RP)
Trial: 22855310
Drug: Non-BIOPATCH (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-BIOPATCH (no patch applied)
Trial: 19898245
Drug: Fluoxetine-clonazepam cotherapy
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine-clonazepam cotherapy
Trial: 19723786
Drug: Fluoxetine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine monotherapy
Trial: 12118025
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and paclitaxel (AT) regimen (doxorubicin 60 mg/m² IV bolus + paclitaxel 175 mg/m² 3-hour infusion)
Trial: 8126635
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g i.v. single dose)
Trial: 8126635
Drug: Cefoxitin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (1 g i.v. three doses)
Trial: 16549839
Drug: Bevacizumab infusion
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab infusion (VEGF antibody blockade)
Trial: 3884806
Drug: Piroxicam, 20
RxNorm normalized name: Piroxicam, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam, 20 mg OD
Trial: 3884806
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated acetylsalicylic acid (EC ASA), 3.9‐5.2 g daily in divided doses
Trial: 29369834
Drug: Oral 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 3% hypertonic saline (HTS)
Trial: 26628478
Drug: Lapatinib 1,250mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,250mg daily plus CapeOx
Trial: 18818415
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) therapy
Trial: 14690186
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous SonoVue contrast echocardiography
Trial: 26194850
Drug: Lipid-Based Nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-Based Nutrient Supplements (LNS)
Trial: 22978102
Drug: Diacerein Capsule
DrugBank: Diacerein (DB11994)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein Capsule (DC)
Trial: 22978102
Drug: Qianggu Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianggu Granule (QGG) + Diacerein Capsule (DC)